Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $16.97, for a total transaction of $55,152.50. The transaction was disclosed in a document filed with the SEC, which is accessible […]

Related Keywords

China , Benjamin Hohl , Enliven Therapeutics Company Profile , Nasdaq , Sg Americas Securities , Exchange Traded Concepts , Mirae Asset Global Investments Co , Enliven Therapeutics Inc , China Universal Asset Management Co , Enliven Therapeutics , Get Free Report , Universal Asset Management , Traded Concepts , Mirae Asset Global Investments , Asset Global Investments , Enliven Therapeutics Daily ,